Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung...
TW's Take: this approval should help accelerate patient enrolling in this program.
Approximately 33% of all non-small cell lung cancer patients in East Asia...
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
TW's Take: ADCs are a hot space right now and RADR could be the key to getting Lantern involved rapidly and cost effectively. Exciting...
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in...
TW's Take: LTRN is starved for clinical data and this program could be a driver of significant value over the coming year as LP-184...
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine...
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of...
TW's Take: RADR is a powerful tool. How Lantern will monetize this remains the biggest question mark around the product. Eventually the value of...
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further...
TW's Take: Lantern's early stage data is compelling and sets the table for these programs, which are nicely funded already, through key milestones.
Non-Hodgkin’s...
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid...
TW's Take: an important step, LP-184 is a potential blockbuster and this program should have results prior to the end of 2023. Lantern, with...
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in...
TW's Take: Lantern's A.I. database for cancer therapeutic development is the largest in the world and positions them to be a leader in ADC...
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform...
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300...
TW's Take: the prior trials of LP-300 showed a dramatic improvement in this smaller subsection of the population, making this trial quite likely to...
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of...
TW's Take: excited for this call as I have long felt that Lantern's LP-184 has billion dollar potential.
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN),...
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical...
TW's Take: Lantern is positioning themselves for success in clinical trials. Once they get rolling, the market should start to pay attention.
DALLAS--(BUSINESS WIRE)-- Lantern...
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of...
TW's Take: this is a positive step but we would like to see many more of these, creating a portfolio of partnering opportunities around...
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product...
TW's Take: more positive progress on this innovative platform. Exactly how they monetize this data is still the question in my mind, but I'm...
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate...
TW's Take: continued execution as they move this incredibly promising drug into human trials sometime in the not too distant future. LTRN still trading...
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC)...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform...
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell...
TW's Take: more exciting but only pre-clinical data for Lantern. The company is positioning itself for an exciting 2023 as they roll into clinical...
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for...
TW's Take: more outstanding pre-clinical data. Lantern will take LP-184 into phase 1 trials in 2023, which should be very interesting for investors.
DALLAS --...
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the...
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic...
TW's Take: LP-184 continues to show interesting results in many different types of cancer. Can't wait to see this get into clinical trials.
DALLAS--(BUSINESS WIRE)-- Lantern...
Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for...
TW's Take: this trial has the potential to change the perception of Lantern as success here would immediately revalue this company. Results expected sometime...
Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the...
TW's Take: good news for Lantern as they can qualify for a PRV (estimated value of $100M) with approval here, which certainly helps the...
Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute – Accelerating Path...
TW's Take: LP-184 has blockbuster potential. Excited to see it enter human trials later this year.
DALLAS, Jan. 12, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a...
Happy New Year!!!
Investing in micro-cap stocks with a 3-5 year time horizon, which is my expectation for a holding period every time I enter a position,...
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at...
TW's Take: more positive pre-clinical data supports the thesis that LP-284 may be effective in several types of rare cancers.
DALLAS, Dec. 14, 2021 /PRNewswire/...
Lantern Pharma Announces Share Repurchase Program
TW's Take: shares of LTRN are incredibly cheap and they have funding for at least 3 years, so this move makes a ton of...
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at...
TW's Take: more positive news on LP-184. This compound, although early in development, looks very promising and has blockbuster potential.
DALLAS, Nov. 11, 2021 /PRNewswire/ -- Lantern...
Asymmetric Risk
Intelligent investing can truly be boiled down to the understanding of risk and reward. In order to properly assess the potential risks of an...
Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation...
TW's Take: another shot on goal here, this time for the enantiomer of LP-184.
DALLAS, Nov. 4, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a...
Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights
TW's Take: with over $73M in cash and a lot of programs moving into trials, Lantern is an amazing risk/reward opportunity.
DALLAS, Nov. 1, 2021...
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion...
TW's Take: continued progress in building out the leading A.I. platform for oncology drug development. The value of RADR is hidden in the share...
Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research &...
TW's Take: yet further evidence that Lantern is on the leading edge in AI adoption and operations in drug development. Will make it easier...
Lantern Pharma Enters into Strategic Collaboration with Deep Lens — Partnership Expected to Accelerate...
TW's Take: Lantern continues to be on the leading edge of combining A.I. and oncology drug development. This partnership should help them not only...
Cash is King
After several weeks of lower stock prices, the market this past week decided that the looming bankruptcy of the world's largest real estate debt...
A September To Remember?
I read this week where someone said, "the short story is always sexier." There's certainly a lot of truth in that. Here in September...
Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support...
TW's Take: Lantern is making all the right moves to set themselves up for long-term success.
DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a...
FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma...
TW's Take: I feel like a broken record when I continually say that LP-184 is proving itself to be a highly potent molecule with...
Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and...
TW's Take: more positive news on LP-184 which we believe has blockbuster potential. GBM is a serious disease with no treatment options for patients....
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation...
TW's Take: LP-184 is a compelling opportunity in multiple cancers. We continue to believe that Lantern is dramatically undervalued relative to the opportunities they...
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment...
TW's Take: more positive news backing development of LP-184, which is proving itself to be a potentially blockbuster drug with potential efficacy in many...
My Saturday Rant…
If you've been reading this newsletter for longer than two weeks, you likely have come to realize that I'm an investor not a trader....
Are We Having Fun Yet? Bull Ride Continues
The "bull" market continued this past week although it showed signs of tiring. Which is good because the bull ride we've been on resembles...
July About to Close With a Bang?
Last week wasn't a bad week for the markets at all. With a nice two day rally to end the week, the Russell 2000...
Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
TW's Take: this is very positive pre-clinical data in a large disease with not many good treatment options. LP-184 is a potentially multi-billion dollar...
Kentucky Bluegrass
In a holiday shortened week, this newsletter comes from Kentucky where the TW household is attending a family wedding. Throw in a side journey...
Let’s Get Ready To Rumble (2nd Half Preview)
To steal a line from Charles Dickens, "It was the best of times. It was the worst of times. Then it was pretty darn...
Hoping for Fireworks
As the market seems to be slowly settling into summer, volatility is dropping and news flow is getting sparse. Amazing to think this is...
Stock Picking Wins This Week
It was another great week for TW as the pendulum appears to be swinging full speed in our direction. This while the overall market...
Reversal of Fortune
The pendulum had swung too far. Simply put, companies that are funded and executing on their gameplan cannot go down forever. Eventually they find...
Lantern Shines During Biotech Blackout
Biotech stocks continue to take it on the chin. This is the result of an overall shift from growth to value in the market...
Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights
DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform...
Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence...
TW's Take: this is very exciting news for Lantern as it is the first time they have licensed their RADR platform for third party...
Alpha-Bet Soup
There are times when stock picking isn't the most important part of your investment strategy. When all that matters is being in the right...
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion...
TW's Take: the rapid growth of datapoints on their A.I. platform is cementing Lantern (LTRN) as a leader in this field. A.I. is changing...
Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum...
TW's Take: our take is that LP-184 has the potential to be a billion dollar or more asset as it has shown potential potency...
The Lows Appear To Be In Place
Earlier this year I was preaching caution. The markets were en fuego and, simply put, this cannot last. While I run pretty fully invested...
A Catalyst Filled Quarter Lies Around The Corner
My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It...
Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor...
TW's Take: LP-184 is a very potent molecule. Combined with the resources of RADR, Lantern continues to find more potential treatments for the drug....
2nd Degree of Risk
Investing in micro-caps always involves a high degree of risk. This risk can come in many different forms as well. For example, looking at...
Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR...
TW's Take: "potentially best in class efficacy" sounds very good to us. LP-184 has great potential in many types of cancer. Lantern has a...
Sitting On My Hands
My Investment Style...It's Not For Everyone But It Works For Me
I'm often asked why I don't trade more often. Many of my stocks make...
Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with...
TW's Take: the stereoisomer of LP-184, which has shown tremendous potential in many solid tumors, this new therapeutic also has many exciting potential uses...
Technically Speaking
I've always thought that technical analysts were like lawyers; you can always find one who will tell you what you want to hear.
That said,...
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights
TW's Take: 2021 is shaping up as an exciting year with many milestones on the calendar, the highlight of which will be multiple IND-enabling...
Blood In The Water
Good Morning Vietnam!
Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like...
When Will The Music Stop?
When you write a newsletter, being speechless is not a great place to be. However, what I'm seeing in the market right now leaves...
Next Up? INmune’s Big Week Finally Arrives
Frequently I hear from investors that something sounds, "too good to be true." And, being honest, more often than not, that's the case. But,...
Lantern Pharma Announces Pricing of $60 Million Public Offering
TW's Take: as usual, the biggest knock on this company was expectations of a financing. With this very large deal over, LTRN is now...
BOOM…Atomera Deal Highlights Another Bull Ride In The Market
Nothing seems to be able to get in the way of this bull market. An insurrection in DC? Yawn. The next administration taking on...
Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors...
TW's Take: we are very excited about this. ADC's are proving to be very effective and also companies focused on this space are in...
Put LP-184, a Potential Blockbuster in the Making, on Your Radar Screen
If you position yourself for success, sometimes you get lucky, right? It’s become common knowledge that A.I. is changing the way all companies do...
Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to...
TW's Take: Hopkins is the world leader in GBM. This announcement means that there are now three leading research institutes working with LP-184 on...
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug...
Tailwinds' Take: LP-184 is proving to be a very valuable drug for fighting multiple types of cancer, especially as a co-therapy with the standard...
The Micro-Cap Rally Continues Full Force
November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index...
Lantern Pharma Earnings Call Transcript
Panna Sharma:
Thank you Marek, and good afternoon to everyone on the call today. Thank you for joining us for our third quarter 2020 conference...
Sell Mortimer, Sell!!!
What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity...
Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress
Tailwinds' Take: crossing a billion datapoints is a big goal achieved ahead of schedule. The platform being developed by Lantern is getting more powerful...
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184,...
Tailwinds' Take: LP-184 has great potential as this collaboration with a leading research institute demonstrates. LTRN's unique AI capabilities have the potential to be...
The Final Push…
Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least.
Yet, here we stand...
Wrapping Up A Chaotic Week
Markets were very volatile this past week, trading back and forth like a game of ping-pong. There's little doubt in my mind that the...
Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on...
Tailwinds' Take: LTRN will benefit greatly from this partnership through development of LP-184 and gobs more data for their machine learning process. This quote...
Under The Radar…Key Data-Points From The Last Week That Nobody Really Noticed
The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in...
Illuminating Lantern Pharma
Today we are initiating coverage of Lantern Pharma (LTRN). Lantern is a clinical stage biopharmaceutical company that uses artificial intelligence, advanced machine learning, genomics,...
Lantern Pharma Announces Upcoming Conference Presentations
DALLAS, Aug. 27, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a
clinical stage biopharmaceutical company using its proprietary RADR^®
artificial intelligence ("A.I.") platform to transform the...
Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress
DALLAS, July 30, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a
clinical stage biotechnology company using its proprietary RADR® artificial
intelligence ("A.I.") platform to improve drug...